Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.11.22	Form 8-K 872589 (RSS)
03.11.22	Form 10-Q 872589 (RSS)
02.11.22	Ausblick: Regeneron Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
02.11.22	Form 4 872589 (RSS)
28.10.22	Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award (PR Newswire)
21.10.22	Regeneron: FDA Grants Pediatric Exclusivity For EYLEA (RTTNews)
21.10.22	Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection (PR Newswire)
19.10.22	Erste Schätzungen: Regeneron Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
14.10.22	Regeneron Pharma: CHMP Adopts Positive Opinion For Libtayo - Quick Facts (RTTNews)
14.10.22	Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer (PR Newswire)
12.10.22	Regeneron: EYLEA SBLA Gets FDA Priority Review - Quick Facts (RTTNews)
12.10.22	EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review (PR Newswire)
11.10.22	Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE (RTTNews)
11.10.22	Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old (PR Newswire)
04.10.22	Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022 (PR Newswire)
03.10.22	Regeneron Elects Dr. Craig B. Thompson to Board of Directors (PR Newswire)
30.09.22	Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO (PR Newswire)
29.09.22	Sanofi-Aktie dennoch schwach: US-Gesundheitsbehörde FDA verkündet Zulassung von Sanofi/Regeneron-Hautmedikament (Dow Jones) Die US-Gesundheitsbehörde FDA hat das Medikament Dupixent von Sanofi und Regeneron Pharmaceuticals zur Behandlung von Patienten mit der seltenen Hautkrankheit Prurigo nodularis zugelassen.» mehr
29.09.22	Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment (RTTNews)
28.09.22	Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis (PR Newswire)
16.09.22	Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels (RTTNews)
16.09.22	Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis (PR Newswire)
16.09.22	Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet (PR Newswire)
15.09.22	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
12.09.22	Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM (PR Newswire)
12.09.22	Regeneron: Fianlimab With Libtayo Shows Greater Than 60% Response Rates In Phase 1 Trial (RTTNews)
12.09.22	Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In... (PR Newswire)
10.09.22	Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors (PR Newswire)
09.09.22	Regeneron Announces Investor Call and Webcast at ESMO 2022 (PR Newswire)
08.09.22	Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis (PR Newswire)
08.09.22	Bayer erreicht Studienziel mit Augenmittel - Wichtig im Konkurrenzkampf (AWP)
08.09.22	Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD (RTTNews)
08.09.22	Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals (PR Newswire)
05.09.22	Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma (PR Newswire)
05.09.22	Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma (RTTNews)
05.09.22	ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers (PR Newswire)
29.08.22	Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria (RTTNews)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
25.08.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
03.08.22	Regeneron Q2 Profit Down On Weak Revenues; Revises FY22 Margin, R&D Outlook (RTTNews)
03.08.22	Regeneron's REGN5678 Shows Encouraging Anti-tumor Activity When Combined With Libtayo (RTTNews)
03.08.22	Regeneron Reports Second Quarter 2022 Financial and Operating Results (PR Newswire)
03.08.22	Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m... (PR Newswire)
02.08.22	Ausblick: Regeneron Pharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
27.07.22	Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease (PR Newswire)
26.07.22	Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
19.07.22	Erste Schätzungen: Regeneron Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
14.07.22	Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal (RTTNews)
14.07.22	Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (PR Newswire)
12.07.22	Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
19.12.24		Optimismus in New York: NASDAQ 100 startet im Plus
17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

24.12.24

Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu

24.12.24

Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone

19.12.24

Optimismus in New York: NASDAQ 100 startet im Plus

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten